This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- TG4010
- DrugBank Accession Number
- DB06584
- Background
A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. 1
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- MVA-Muc1-IL2
- External IDs
- TG 4010
- TG4010
Pharmacology
- Indication
Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UMucin-1 Not Available Humans UInterleukin-2 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of TG4010 can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of TG4010 can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of TG4010 can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of TG4010 can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of TG4010 can be decreased when used in combination with Alemtuzumab. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- WQQ9XZH2CC
- CAS number
- 350485-85-7
References
- General References
- NCI Drug Dictionary: MVA-MUC1-IL2 vaccine [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Lung Cancer, Nonsmall Cell, Stage I / Lung Cancer, Nonsmall Cell, Stage IIIA / Nonsmall Cell Lung Cancer, Stage II / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-small Cell Lung Cancer (NSCLC) 1 2 Completed Treatment Metastatic Non-Small Cell Lung Cancer 1 2 Terminated Treatment Neoplasms of the Prostate 1 2, 3 Completed Treatment Non-Small Cell Lung Carcinoma 1 2, 3 Terminated Treatment Non-Small Cell Lung Carcinoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Transcription cofactor activity
- Specific Function
- The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.The ...
- Gene Name
- MUC1
- Uniprot ID
- P15941
- Uniprot Name
- Mucin-1
- Molecular Weight
- 122100.89 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Kinase activator activity
- Specific Function
- Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimu...
- Gene Name
- IL2
- Uniprot ID
- P60568
- Uniprot Name
- Interleukin-2
- Molecular Weight
- 17627.52 Da
Drug created at March 19, 2008 16:38 / Updated at June 12, 2020 16:52